ad image

Company Info

Teva Pharmaceutical Industries

Teva Pharmaceutical Industries

Drug Discovery & Development

Overview

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global leader in generic medicines, with innovative treatments in select areas, including CNS, pain and respiratory. We deliver high-quality generic products and medicines in nearly every therapeutic area to address unmet patient needs. We have an established presence in generics, specialty, OTC and API, building on more than a century-old legacy, with a fully integrated R&D function, strong operational base and global infrastructure and scale. We strive to act in a socially and environmentally responsible way. Headquartered in Israel, with production and research facilities around the globe, we employ 45,000 professionals, committed to improving the lives of millions of patients. 
Teva Pharmaceutical Industries
Contributions
15 Contributions1 / 1
Teva Pharmaceutical Industries
Recall

Teva Pharmaceuticals USA, Inc. Initiates Voluntary Nationwide Recall of Metformin Hydrochloride

Teva Pharmaceutical Industries

PR-M06-20-NI-025-1496Jun 18, 2020
Teva Pharmaceutical Industries
EpiPen

Teva Announces Availability of a Generic Equivalent of EpiPen Jr in the United States

Teva Pharmaceutical Industries

PR-M08-19-NI-069Aug 23, 2019
Teva Pharmaceutical Industries
Generics

Teva Announces Launch of a Generic Version of Tarceva® (erlotinib) Tablets in the United States

Teva Pharmaceutical Industries

PR-M05-19-NI-045May 15, 2019
Teva Pharmaceutical Industries
Clinical Development

Teva Announces Update on Fremanezumab Clinical Development for use in Episodic Cluster Headache

Teva Pharmaceutical Industries

PR-M04-19-NI-077Apr 24, 2019
Teva Pharmaceutical Industries
Generics

Teva Announces Launch of a Generic Version of VESIcare® (solifenacin succinate) Tablets in the United States

Teva Pharmaceutical Industries

PR-M04-19-NI-072Apr 23, 2019
Teva Pharmaceutical Industries
Generics

Teva Announces Launch of ALYQ™ (Tadalafil Tablets USP), a Generic Version of ADCIRCA® in the United States

Teva Pharmaceutical Industries

PR-M02-19-NI-014Feb 07, 2019
Teva Pharmaceutical Industries
Study Results

Regeneron and Teva Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip

Teva Pharmaceutical Industries

PR-M09-18-NI-059Sep 20, 2018
Teva Pharmaceutical Industries
Study Results

Teva and Regeneron Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip

Teva Pharmaceutical Industries

PR-M09-18-NI-051Sep 18, 2018
Teva Pharmaceutical Industries
Announcement

Governor Murphy Announces Teva Pharmaceuticals to Locate US Headquarters in New Jersey

Teva Pharmaceutical Industries

PR-M07-18-NI-025Jul 09, 2018
Teva Pharmaceutical Industries
Clinical Data

Teva Presents New Long-Term Data Demonstrating Efficacy and Safety of COPAXONE® (glatiramer acetate injection) 40 mg/mL

Teva Pharmaceutical Industries

PR-M05-18-NI-013May 02, 2018
Teva Pharmaceutical Industries
Generic

Teva Announces the Launch of a Generic Version of Lialda® in the United States

Teva Pharmaceutical Industries

PR-M03-18-NI-100-4488Mar 28, 2018
Teva Pharmaceutical Industries
Inhalation

Teva Announces U.S. Launch of QVAR® RediHaler™ (Beclomethasone Dipropionate HFA) Inhalation Aerosol

Teva Pharmaceutical Industries

PR-M02-18-NI-53Feb 15, 2018
Teva Pharmaceutical Industries
Generics

Teva Announces Launch of a Generic Version of Syprine® in the United States

Teva Pharmaceutical Industries

PR-M02-18-NI-050Feb 14, 2018
Teva Pharmaceutical Industries
FDA Approval

Teva Announces U.S. FDA Approval of TRISENOX® (arsenic trioxide) Injection for First Line Treatment of Acute Promyelocytic Leukemia

Teva Pharmaceutical Industries

PR-M01-18-NI-053Jan 18, 2018
Teva Pharmaceutical Industries
Drug Development

Teva Announces Sale of PARAGARD® (intrauterine copper contraceptive) to CooperSurgical

Teva Pharmaceutical Industries

PR-M08-17-NI-014Sep 12, 2017
1 / 1
0 Contributors1 / 0

No authors found

1 / 0